Premium
Pediatric microdose and microtracer studies using 14 C in Europe
Author(s) -
Turner MA,
Mooij MG,
Vaes WHJ,
Windhorst AD,
Hendrikse NH,
Knibbe CAJ,
Kõrgvee LT,
Maruszak W,
Grynkiewicz G,
Garner RC,
Tibboel D,
Park BK,
de Wildt SN
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.163
Subject(s) - microdose , medicine , medical physics , engineering ethics , medical education , pharmacology , engineering
Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using 14 C‐labeled probes in Europe to illustrate the strengths and limitations of these approaches.